目的探讨不同治疗方法对难治与复发性多发性骨髓瘤预后的影响。方法对30例难治与复发性多发性骨髓瘤进行不同的分组治疗及长期随访,观察缓解率和生存期。结果影响多发性骨髓瘤生存的主要因素是年龄>60岁。在提高缓解率方面,三氧化二砷(AS2O3)组优于联合化疗组和化疗加干扰素组,分别为47.2%、20.3%、22.3%。结论AS2O3治疗难治或复发性多发性骨髓瘤疗效显著,不良反应轻微,患者易耐受。 Objective To investigate the influence of different treatment methods on the prognosis of refractory and recurrent multiple myeloma. Methods Thirty patients with refractory and recurrent multiple myeloma were divided into different groups and followed up for a long time. The remission rate and survival rate were observed. The main factors affecting the survival of multiple myeloma were age> 60 years. In improving the response rate, arsenic trioxide (AS2O3) group was superior to the combined chemotherapy group and chemotherapy plus interferon group, respectively, 47.2%, 20.3%, 22.3%. Conclusion AS2O3 treatment of refractory or recurrent multiple myeloma significant effect, minor adverse reactions, patients with easy tolerance.